In the phase III IMpassion130 trial, atezolizumab improved PFS when added to first-line nab-paclitaxel in metastatic triple-negative breast cancer (TNBC) in the entire study population, but OS was only prolonged in patients with tumors bearing PD-L1-positive immune cells.3 These results led to regulatory approval in the first-line setting for PD-L1-positive disease. The gene discussed is CD274; the disease is triple-negative breast carcinoma.